16/06/2026 Avalo Therapeutics added AVTX-010, a long-acting next-generation anti-IL-1β antibody, to Its development pipeline Avalo Therapeutics added AVTX-010, a long-acting next-generation anti-IL-1β antibody, to Its development pipeline (Ref) Avalo Therapeutics announced the advancement of AVTX-010 (anti-IL-1β mAb) with the potential for development in hidradenitis suppurativa (HS) as well as additional inflammatory disorders. The Company expected to submit an Investigation